SlideShare a Scribd company logo
Reversal Of Antithrombotic Agents
DR ANKIT GAJJAR
MD,IDCCM,IFCCM,EDIC
Consultant Intensivist at INS Hospital, Surat
Antithrombotic Agents
• Anti platelet drugs…. Aspirin, Clopidogrel
• Anti coagulants
Parenteral
UFH
LMWH…. Enoxaparin, Dalteparin
Fondaparinux
Oral
Warfarin
NOAC
• Thrombolysis
Vascular Injury
Exposure of collagen and vWF Tissue factor exposure
Platelet adhesion and release Activation of coagulation
Platelet recruitment and activation Thrombin generation
Fibrin formationPlatelet aggregation
Platelet – fibrin thrombus
• Drugs used in thrombosis
• Anticoagulants: drugs which prevent clotting by inhibiting clotting factors
(coagulation process) (used in prevention and treatment of thrombosis).
• Antiplatelets: drugs which prevent and inhibit platelet activation and
aggression (used as prophylactic therapy in high risk patients).
• Thrombolytics or Fibrinolytics: act by dissolving existing or already formed
thrombi or emboli and used in the acute treatment of thrombosis.
•
Anti platelet drugs
The role of platelets
The role of platelets
The role of platelets
The role of platelets
Plaque Disruption
Collagen vWF
Platelet adhesion and secretion
Aspirin
Ticlopidine
Clopidogrel
Abciximab
Eptifibatide
Tirofiban
Platelet aggregation
Platelet recruitment and activation
COX-1
ADP
GPllb / llla activation
X
Mechanisms of action of
antiplatelet drugs
X
TXA2
Antiplatelet Agents
• Aspirin
Irreversibly inhibit COX 1 enzyme
Rapid onset <1 hr
Half life 15- 30 minutes
5-7 days for platelet recovery
Antiplatelet Agents
• Clopidogrel
• Irreversibly inhibit ADP receptor subtype P2Y12 receptor,
required for platelet activation
• Half life 8 hrs
• 5 days for platelet recovery
Antiplatelet Agents
• Mixing of Aspirin treated platelets ex-vivo, with 30-50 %
untreated donor platelets, restored abnormal platelets
aggregation response. So, infusion of 2-3 adult dose of donor
platelets are effective in emergency reversal of aspirin in
adults.
Vilahur et al 2007
Li et al 2012
British journal of Haematology 2012, 160, 35-46
Antiplatelet Agents
• Reversal
Elective surgery wait for 5-7 days
For emergency surgery, replacement with platelet transfusion
should be consider
For conservative management, platelet transfusion is not
recommended (risk/benefit ratio)
Desmopressin (0.4 micrg/kg) can be consider spcifically in patient
with Uremia
No role of FFP and Protamine
Dastur CK, Stroke and Vascular Neurology 2017
Anti coagulants
UFH
• Acts on intrinsic pathway
• Inactivates IX, X, XI and XII and thrombin and inhibit conversion of
fibrinogen to fibrin
• Metabolized in liver and reticulo endothelial system
• No Renal adjustment
• Dose : 60-80 Unit/kg bolus f/b 12-18 Unit/kg/hr
Px - 5000 Unit Bd / Tid
• Monitoring by aPTT level
• Does not affect Prothrombin Time
UFH
• Shorter half life 30-90 minutes
• Reversal
If stopped before 4 hours, no need of any reversal
If infusion is going on, calculate last 2-2.5 hours of heparin and give
protamine sulphate 1 mg/100 unit of heparin (maximum 50 mg)
If dose unknown, give 50 mg of protamine
100 % reversal effect
Mesure aPTT before OT
No role of FFP or Vitamin K
LMWH
• Enoxaparin and Dalteparin
• Inhibit factor X>II
• Does not affect aPTT and PT level
• Renal clearance, so dose adjustment in renal failure
• Dose: Therapeutic - I mg/kg bid or 1.5 mg/kg od
(1 mg/kg od in renal failure)
Prophylactic – 40 mg sc od
• No need of monitoring (factor Anti Xa level can be monitored
in special case)
LMWH
• Reversal
For elective surgery, stop before 24 hours
For immediate reversal,
- last dose < 8 hours – 1 mg protamine / 1 mg enoxaparin
(additional 0.5 mg protamine / 1 mg enoxaparin can be used)
- last dose 8-12 hours – 0.5 mg protamine / 1 mg enoxaparin
60 % reversal
No use of FFP or Vitamin K
Fondaparinux
• Indirect Factor Xa inhibitor
• Does not affect aPTT and PT
• No need of monitoring
• Renal clearance (C/I if CrCl < 30 ml/min)
• Dose : Prophylactic : 2.5 mg sc od
Therapeutic : < 50 kg 5 mg sc od
50-100 kg 7.5 mg sc od
> 100 kg 10 mg sc od
Fondaparinux
• Reversal
Elective surgery stop before 24 hours
No agent for immediate reversal
Factor VIIa can be try
Warfarin
• Inhibit Vitamin K dependent factor II, VII, IX and X
• Mesure PT for dose adjustment
• Half life 36 hrs.
• 5 days for INR to become normal
• Target INR 2-3
Warfarin
• For immediate reversal of INR
• Inj vit K 10 mg iv with PCC or FFP
• PCC – 4 factor or 3 factor PCC 1500-2000 IU
 Cost and availability
 Rapid and specific reversal
• FFP – 15 – 20 ml/kg (6-8 units of FFP)
 Shorter duration of action
 large volume infusion and more complication
 Slow reversal than PCC
Target INR <1.5
Warfarin
• Factor VIIa can be used
• No role of protamine sulphate
Warfarin
• Supratherapeutic INR without bleeding
• INR 5-9 – omit 1-2 dose+- 1.25 -5 mg PO vitamin K
• INR >9 ( no bleed )- omit 1-2 dose +/- 2.5 - 5 mg PO vitamin K
• Surgery Reversal
INR > 1.5-2.5 hrs.
• Sx <24 hrs – 0.5 -1 mg IV vit.K x1 +/- 5-8 ml/kg FFP
• Sx 24-96 hrs- 0.5 -1 mg PO vitamin K
INR > 2.5 – 5
• Sx <24 hrs – 1-2.5 IV Vitamin K +/- 5-8ml /kg FFP
• Sx 24-96 hrs – 1-2.5 mg PO vitamin K
Warfarin
• For elective surgery
• Stop warfarin before 5 days
• Switch over to UFH / LMWH
• Stop UFH / LMWH before surgery
Dabigatran
• NOAC
• Direct thrombin inhibitor (Argatroban, bivalirudin)
• Dose : 150 mg PO bd
if CrCl 15-30 ml/min – 75 mg PO bd
• No need of monitoring for therapeutic effect but Thrombin
time will be elevated
• No use of FFP or Protamine
• Indication : Stroke prevention in non valvular AF
Dabigatran
• Reversal
• For elective surgery, stop before 24 hours
• For emergency reversal, Idarucizumab (Praxbind®)
Infuse two 2.5 gram/50 mL vials undiluted over 5-10 minutes each
- Second vial should be infused within 15 minutes of first vial
• Activated Charcoal – within 1 hr. of Dabigatran
• Dialysis – Last resort, removes 60% of dabigatran(mainly in renal failure)
• 4 factor PCC (50 unit/kg) if Praxibind is not available
• Factor VIIa can be tried
• A normal aPTT and TT rules out clinically relavent Dabigatran effect.
Factor Xa inhibitors
• Rivaroxaban, Apixaban, Edoxaban
• Elective surgery – stop before 24 hours
• Emergency reversal
• If presenting within 2 hours of intake – activated charcoal
• 4 factor PCC – 50 units / kg
• Laboratory testing not helpful
• Not dialysable
Thrombolytic agents
Thrombolytic agents
• Cryoprecipitate 10 units
• If fibrinogen <150 mg/dl post cryoprecipitate, consider
additional cryoprecipitate
• 6-8 unit of platelet concentrate
• If cryoprecipitate not available, FFP can be given
• If not available, than tranexamic acid 15-20 ml/kg
Protamine Sulphate
• Protamine is basic in nature and combine with acidic heparin
• Calculate dose
• Maximum dose 50 mg (1 ampoule)
• Severe Allergic reaction
• Administration
Dilute in 5 ml of sterile water
Inject over 10 minutes
TAKE HOME MESSAGE
DRUG Elective Emergency Not indicated Monitoring
Aspirin
Clopidogrel
Stop before 5-7 days Platelet concentrate
Desmopressin
(Uremia)
FFP
Vitamin K
Protamine
None
UFH Stop before 4-6
hours
Protamine Sulphate
(100%)
FFP
Vitamin K
aPTT
LMWH Stop before 24 hours Protamine Sulphate
(60 %)
FFP
Vitamin K
Anti Xa level
Fondaperinux Stop before 24 hours FVIIa FFP
Vitamin K
Protamine
Anti Xa level
Warfarin Stop before 5-7 days Vitamin K
4 PCC 50 Unit/kg
FFP 15-20 ml/kg
Protamine PT
Drug Elective Emergency Not indicated Monitoring
Dabigatran Stop before 24 hours Activated Charcoal
Praxbind 5 gm
4 factor PCC
Dialysis
FFP
Vitamin K
Protamine
TT
aPTT
Rivaroxaban Stop before 24 hours Activated Charcoal
4 factor PCC
FFP
Vitamin K
Protamine
Dialysis
None
Thrombolytics --- 10 Cryoprecipitate
6-8 RDP
FFP
---- Fibrinogen
Thank you

More Related Content

What's hot

New oral anticoagulants (NOAC) WATAG guidelines
New oral anticoagulants (NOAC) WATAG guidelinesNew oral anticoagulants (NOAC) WATAG guidelines
New oral anticoagulants (NOAC) WATAG guidelines
SCGH ED CME
 
Fibrinolytic treatment of acute myocardial infarction by tenecteplase
Fibrinolytic treatment of acute myocardial infarction by tenecteplaseFibrinolytic treatment of acute myocardial infarction by tenecteplase
Fibrinolytic treatment of acute myocardial infarction by tenecteplase
desktoppc
 
New oral anticoagulant shivaomfinal noac
New oral anticoagulant shivaomfinal noacNew oral anticoagulant shivaomfinal noac
New oral anticoagulant shivaomfinal noac
Shivaom Chaurasia
 
Reversal of anticoagulation (joel 31.1.2017)
Reversal of anticoagulation (joel 31.1.2017)Reversal of anticoagulation (joel 31.1.2017)
Reversal of anticoagulation (joel 31.1.2017)
Joel Chiang
 
new oral anticoagulants
new oral anticoagulantsnew oral anticoagulants
new oral anticoagulants
derosaMSKCC
 
NOAC( Novel Oral Anticoagulants) uses in the current era
NOAC( Novel Oral Anticoagulants) uses in the current eraNOAC( Novel Oral Anticoagulants) uses in the current era
NOAC( Novel Oral Anticoagulants) uses in the current era
PROFESSOR DR. MD. TOUFIQUR RAHMAN
 
Anticoagulants (VK)
Anticoagulants (VK)Anticoagulants (VK)
Anticoagulants (VK)
Dr. Abhavathi Vijay Kumar
 
Heparin and enoxaparin
Heparin and enoxaparinHeparin and enoxaparin
Heparin and enoxaparin
Christian Medical College & Hospital
 
Ticagrelor
TicagrelorTicagrelor
Ticagrelor
Himanshu Rana
 
Gp2b3a
Gp2b3aGp2b3a
Oral apixaban
Oral apixabanOral apixaban
Oral apixaban
Aziza Alamri - UOD
 
Doacs by dr hafeesh fazulu
Doacs by dr hafeesh fazuluDoacs by dr hafeesh fazulu
Doacs by dr hafeesh fazulu
Hafeesh Fazulu
 
Antiplatelet therapy
Antiplatelet therapyAntiplatelet therapy
Antiplatelet therapy
Arindam Pande
 
Arni
ArniArni
UFH & LMWH & fondaparinux
UFH & LMWH & fondaparinuxUFH & LMWH & fondaparinux
UFH & LMWH & fondaparinux
Mohammed Adel
 
Rivaroxaban (XARELTO)
Rivaroxaban (XARELTO)Rivaroxaban (XARELTO)
Rivaroxaban (XARELTO)
Ankit Raiyani
 
Anticoagulation and dvt
Anticoagulation and dvtAnticoagulation and dvt
Anticoagulation and dvt
Jibran Mohsin
 
Anticoagulation in neurosurgery heparin warfarin_ppt
Anticoagulation in neurosurgery heparin warfarin_pptAnticoagulation in neurosurgery heparin warfarin_ppt
Anticoagulation in neurosurgery heparin warfarin_ppt
MQ_Library
 
Rivaroxaban
RivaroxabanRivaroxaban
Rivaroxaban
M Vojdan parast
 
Important Clinical Trials In Cardiology - An Overview 2016-17
Important Clinical Trials In Cardiology - An Overview 2016-17Important Clinical Trials In Cardiology - An Overview 2016-17
Important Clinical Trials In Cardiology - An Overview 2016-17
Amit Verma
 

What's hot (20)

New oral anticoagulants (NOAC) WATAG guidelines
New oral anticoagulants (NOAC) WATAG guidelinesNew oral anticoagulants (NOAC) WATAG guidelines
New oral anticoagulants (NOAC) WATAG guidelines
 
Fibrinolytic treatment of acute myocardial infarction by tenecteplase
Fibrinolytic treatment of acute myocardial infarction by tenecteplaseFibrinolytic treatment of acute myocardial infarction by tenecteplase
Fibrinolytic treatment of acute myocardial infarction by tenecteplase
 
New oral anticoagulant shivaomfinal noac
New oral anticoagulant shivaomfinal noacNew oral anticoagulant shivaomfinal noac
New oral anticoagulant shivaomfinal noac
 
Reversal of anticoagulation (joel 31.1.2017)
Reversal of anticoagulation (joel 31.1.2017)Reversal of anticoagulation (joel 31.1.2017)
Reversal of anticoagulation (joel 31.1.2017)
 
new oral anticoagulants
new oral anticoagulantsnew oral anticoagulants
new oral anticoagulants
 
NOAC( Novel Oral Anticoagulants) uses in the current era
NOAC( Novel Oral Anticoagulants) uses in the current eraNOAC( Novel Oral Anticoagulants) uses in the current era
NOAC( Novel Oral Anticoagulants) uses in the current era
 
Anticoagulants (VK)
Anticoagulants (VK)Anticoagulants (VK)
Anticoagulants (VK)
 
Heparin and enoxaparin
Heparin and enoxaparinHeparin and enoxaparin
Heparin and enoxaparin
 
Ticagrelor
TicagrelorTicagrelor
Ticagrelor
 
Gp2b3a
Gp2b3aGp2b3a
Gp2b3a
 
Oral apixaban
Oral apixabanOral apixaban
Oral apixaban
 
Doacs by dr hafeesh fazulu
Doacs by dr hafeesh fazuluDoacs by dr hafeesh fazulu
Doacs by dr hafeesh fazulu
 
Antiplatelet therapy
Antiplatelet therapyAntiplatelet therapy
Antiplatelet therapy
 
Arni
ArniArni
Arni
 
UFH & LMWH & fondaparinux
UFH & LMWH & fondaparinuxUFH & LMWH & fondaparinux
UFH & LMWH & fondaparinux
 
Rivaroxaban (XARELTO)
Rivaroxaban (XARELTO)Rivaroxaban (XARELTO)
Rivaroxaban (XARELTO)
 
Anticoagulation and dvt
Anticoagulation and dvtAnticoagulation and dvt
Anticoagulation and dvt
 
Anticoagulation in neurosurgery heparin warfarin_ppt
Anticoagulation in neurosurgery heparin warfarin_pptAnticoagulation in neurosurgery heparin warfarin_ppt
Anticoagulation in neurosurgery heparin warfarin_ppt
 
Rivaroxaban
RivaroxabanRivaroxaban
Rivaroxaban
 
Important Clinical Trials In Cardiology - An Overview 2016-17
Important Clinical Trials In Cardiology - An Overview 2016-17Important Clinical Trials In Cardiology - An Overview 2016-17
Important Clinical Trials In Cardiology - An Overview 2016-17
 

Similar to Reversal of antithrombotic agent

Drugs used in cath lab
Drugs used in cath labDrugs used in cath lab
Drugs used in cath lab
Farrukh Masood
 
Drugs influencing coagulation .pptx
Drugs influencing coagulation .pptxDrugs influencing coagulation .pptx
Drugs influencing coagulation .pptx
Ahmed El Kacer
 
Anesthesia in patients on anti coagulants
Anesthesia in patients on anti coagulantsAnesthesia in patients on anti coagulants
Anesthesia in patients on anti coagulants
Navin Jain‬
 
Anticoagulants and antiplatelet agents
Anticoagulants and antiplatelet agentsAnticoagulants and antiplatelet agents
Anticoagulants and antiplatelet agents
tulsimd
 
Heparin .pdf
Heparin .pdfHeparin .pdf
Heparin .pdf
UVAS
 
Anticoagulation in Deep Vein Thrombosis (According to American College of Che...
Anticoagulation in Deep Vein Thrombosis (According to American College of Che...Anticoagulation in Deep Vein Thrombosis (According to American College of Che...
Anticoagulation in Deep Vein Thrombosis (According to American College of Che...
Jibran Mohsin
 
Tocolytic Drugs.pptx
Tocolytic Drugs.pptxTocolytic Drugs.pptx
Tocolytic Drugs.pptx
Asikin Sakri
 
POCKET DE ANTICOAGULANTES.pdf
POCKET DE ANTICOAGULANTES.pdfPOCKET DE ANTICOAGULANTES.pdf
POCKET DE ANTICOAGULANTES.pdf
BrendaLara60
 
Dvt prophalaxis
Dvt prophalaxisDvt prophalaxis
Dvt prophalaxis
Dr Sharanprasad Hongal
 
Antiplatelets
Antiplatelets  Antiplatelets
Antiplatelets
Dr. Rupendra Bharti
 
SBP (National Hepatic Institute)
SBP (National Hepatic Institute)SBP (National Hepatic Institute)
SBP (National Hepatic Institute)
Mohamed Moustafa
 
A role of anticoagulation in neurocritical care jhjk
A role of anticoagulation in  neurocritical care jhjkA role of anticoagulation in  neurocritical care jhjk
A role of anticoagulation in neurocritical care jhjk
Ankit Gajjar
 
Oral-Anti coagulants
Oral-Anti coagulantsOral-Anti coagulants
Oral-Anti coagulants
Amarendra Edara
 
ANTIPLATELET DRUGS.pptx
ANTIPLATELET DRUGS.pptxANTIPLATELET DRUGS.pptx
ANTIPLATELET DRUGS.pptx
Awais irshad
 
Anticoagulants Nursing esther
Anticoagulants Nursing estherAnticoagulants Nursing esther
Anticoagulants Nursing esther
Esther Mary Mathew
 
Anticoagulation Pharmacology
Anticoagulation PharmacologyAnticoagulation Pharmacology
Anticoagulation Pharmacology
Peninsula Coastal Region of Sutter Health
 
Pharmacology of Anticoagulants, antiplatelets
 Pharmacology of Anticoagulants, antiplatelets Pharmacology of Anticoagulants, antiplatelets
Pharmacology of Anticoagulants, antiplatelets
sunil kumar daha
 
Antixcoagulants
AntixcoagulantsAntixcoagulants
Antixcoagulants
Chintan Doshi
 
Anticoagulants.ppt
Anticoagulants.pptAnticoagulants.ppt
Anticoagulants.ppt
Ahmed El Kacer
 
Blood presentation
Blood presentation Blood presentation
Blood presentation
India CTVS
 

Similar to Reversal of antithrombotic agent (20)

Drugs used in cath lab
Drugs used in cath labDrugs used in cath lab
Drugs used in cath lab
 
Drugs influencing coagulation .pptx
Drugs influencing coagulation .pptxDrugs influencing coagulation .pptx
Drugs influencing coagulation .pptx
 
Anesthesia in patients on anti coagulants
Anesthesia in patients on anti coagulantsAnesthesia in patients on anti coagulants
Anesthesia in patients on anti coagulants
 
Anticoagulants and antiplatelet agents
Anticoagulants and antiplatelet agentsAnticoagulants and antiplatelet agents
Anticoagulants and antiplatelet agents
 
Heparin .pdf
Heparin .pdfHeparin .pdf
Heparin .pdf
 
Anticoagulation in Deep Vein Thrombosis (According to American College of Che...
Anticoagulation in Deep Vein Thrombosis (According to American College of Che...Anticoagulation in Deep Vein Thrombosis (According to American College of Che...
Anticoagulation in Deep Vein Thrombosis (According to American College of Che...
 
Tocolytic Drugs.pptx
Tocolytic Drugs.pptxTocolytic Drugs.pptx
Tocolytic Drugs.pptx
 
POCKET DE ANTICOAGULANTES.pdf
POCKET DE ANTICOAGULANTES.pdfPOCKET DE ANTICOAGULANTES.pdf
POCKET DE ANTICOAGULANTES.pdf
 
Dvt prophalaxis
Dvt prophalaxisDvt prophalaxis
Dvt prophalaxis
 
Antiplatelets
Antiplatelets  Antiplatelets
Antiplatelets
 
SBP (National Hepatic Institute)
SBP (National Hepatic Institute)SBP (National Hepatic Institute)
SBP (National Hepatic Institute)
 
A role of anticoagulation in neurocritical care jhjk
A role of anticoagulation in  neurocritical care jhjkA role of anticoagulation in  neurocritical care jhjk
A role of anticoagulation in neurocritical care jhjk
 
Oral-Anti coagulants
Oral-Anti coagulantsOral-Anti coagulants
Oral-Anti coagulants
 
ANTIPLATELET DRUGS.pptx
ANTIPLATELET DRUGS.pptxANTIPLATELET DRUGS.pptx
ANTIPLATELET DRUGS.pptx
 
Anticoagulants Nursing esther
Anticoagulants Nursing estherAnticoagulants Nursing esther
Anticoagulants Nursing esther
 
Anticoagulation Pharmacology
Anticoagulation PharmacologyAnticoagulation Pharmacology
Anticoagulation Pharmacology
 
Pharmacology of Anticoagulants, antiplatelets
 Pharmacology of Anticoagulants, antiplatelets Pharmacology of Anticoagulants, antiplatelets
Pharmacology of Anticoagulants, antiplatelets
 
Antixcoagulants
AntixcoagulantsAntixcoagulants
Antixcoagulants
 
Anticoagulants.ppt
Anticoagulants.pptAnticoagulants.ppt
Anticoagulants.ppt
 
Blood presentation
Blood presentation Blood presentation
Blood presentation
 

More from Ankit Gajjar

MALARIA.pptx
MALARIA.pptxMALARIA.pptx
MALARIA.pptx
Ankit Gajjar
 
CLOSTRIDIUM DIIFFICICLE.ppt
CLOSTRIDIUM DIIFFICICLE.pptCLOSTRIDIUM DIIFFICICLE.ppt
CLOSTRIDIUM DIIFFICICLE.ppt
Ankit Gajjar
 
ORGANOPHOSPHORUS POISIONING.pptx
ORGANOPHOSPHORUS POISIONING.pptxORGANOPHOSPHORUS POISIONING.pptx
ORGANOPHOSPHORUS POISIONING.pptx
Ankit Gajjar
 
OCCUPATIONAL HEALTH ISSUES RELATED TO GASTROINTESTINAL TRACT.pptx
OCCUPATIONAL HEALTH ISSUES RELATED TO GASTROINTESTINAL TRACT.pptxOCCUPATIONAL HEALTH ISSUES RELATED TO GASTROINTESTINAL TRACT.pptx
OCCUPATIONAL HEALTH ISSUES RELATED TO GASTROINTESTINAL TRACT.pptx
Ankit Gajjar
 
FLUID THERAPY AND ELECTROLYTE MANAGEMENT final.pptx
FLUID THERAPY AND ELECTROLYTE MANAGEMENT final.pptxFLUID THERAPY AND ELECTROLYTE MANAGEMENT final.pptx
FLUID THERAPY AND ELECTROLYTE MANAGEMENT final.pptx
Ankit Gajjar
 
Balance fluid therapy.pptx
Balance fluid therapy.pptxBalance fluid therapy.pptx
Balance fluid therapy.pptx
Ankit Gajjar
 
Lifestyle diseases
Lifestyle diseasesLifestyle diseases
Lifestyle diseases
Ankit Gajjar
 
Calcium metabolism hypercalcemia
Calcium metabolism hypercalcemiaCalcium metabolism hypercalcemia
Calcium metabolism hypercalcemia
Ankit Gajjar
 
TB MENINGITIS and anti tuberculous drugs
TB MENINGITIS and anti tuberculous drugsTB MENINGITIS and anti tuberculous drugs
TB MENINGITIS and anti tuberculous drugs
Ankit Gajjar
 
Basic ventilatory parameters
Basic ventilatory parametersBasic ventilatory parameters
Basic ventilatory parameters
Ankit Gajjar
 
AHA BLS
AHA BLSAHA BLS
AHA BLS
Ankit Gajjar
 
Abg interpretation copy
Abg interpretation   copyAbg interpretation   copy
Abg interpretation copy
Ankit Gajjar
 
Trouble shooting of mechanical ventilator
Trouble shooting of mechanical ventilatorTrouble shooting of mechanical ventilator
Trouble shooting of mechanical ventilator
Ankit Gajjar
 
ACUTE MANAGEMENT OF Hyperkalemia
ACUTE MANAGEMENT OF Hyperkalemia ACUTE MANAGEMENT OF Hyperkalemia
ACUTE MANAGEMENT OF Hyperkalemia
Ankit Gajjar
 
diagnosis and management of mdr iai role of carbapenems and tigecycli.._
diagnosis and management of mdr iai role of carbapenems and  tigecycli.._diagnosis and management of mdr iai role of carbapenems and  tigecycli.._
diagnosis and management of mdr iai role of carbapenems and tigecycli.._
Ankit Gajjar
 
Role of vitamin c and thiamine in sepsis
Role of vitamin c and thiamine in sepsisRole of vitamin c and thiamine in sepsis
Role of vitamin c and thiamine in sepsis
Ankit Gajjar
 
NUTRITION IN CRITICAL CARE
NUTRITION IN CRITICAL CARENUTRITION IN CRITICAL CARE
NUTRITION IN CRITICAL CARE
Ankit Gajjar
 
Aspiration pneumonia
Aspiration pneumoniaAspiration pneumonia
Aspiration pneumonia
Ankit Gajjar
 
Ventilation in acute heart failure
Ventilation in acute heart failureVentilation in acute heart failure
Ventilation in acute heart failure
Ankit Gajjar
 
Ulinastatin final
Ulinastatin finalUlinastatin final
Ulinastatin final
Ankit Gajjar
 

More from Ankit Gajjar (20)

MALARIA.pptx
MALARIA.pptxMALARIA.pptx
MALARIA.pptx
 
CLOSTRIDIUM DIIFFICICLE.ppt
CLOSTRIDIUM DIIFFICICLE.pptCLOSTRIDIUM DIIFFICICLE.ppt
CLOSTRIDIUM DIIFFICICLE.ppt
 
ORGANOPHOSPHORUS POISIONING.pptx
ORGANOPHOSPHORUS POISIONING.pptxORGANOPHOSPHORUS POISIONING.pptx
ORGANOPHOSPHORUS POISIONING.pptx
 
OCCUPATIONAL HEALTH ISSUES RELATED TO GASTROINTESTINAL TRACT.pptx
OCCUPATIONAL HEALTH ISSUES RELATED TO GASTROINTESTINAL TRACT.pptxOCCUPATIONAL HEALTH ISSUES RELATED TO GASTROINTESTINAL TRACT.pptx
OCCUPATIONAL HEALTH ISSUES RELATED TO GASTROINTESTINAL TRACT.pptx
 
FLUID THERAPY AND ELECTROLYTE MANAGEMENT final.pptx
FLUID THERAPY AND ELECTROLYTE MANAGEMENT final.pptxFLUID THERAPY AND ELECTROLYTE MANAGEMENT final.pptx
FLUID THERAPY AND ELECTROLYTE MANAGEMENT final.pptx
 
Balance fluid therapy.pptx
Balance fluid therapy.pptxBalance fluid therapy.pptx
Balance fluid therapy.pptx
 
Lifestyle diseases
Lifestyle diseasesLifestyle diseases
Lifestyle diseases
 
Calcium metabolism hypercalcemia
Calcium metabolism hypercalcemiaCalcium metabolism hypercalcemia
Calcium metabolism hypercalcemia
 
TB MENINGITIS and anti tuberculous drugs
TB MENINGITIS and anti tuberculous drugsTB MENINGITIS and anti tuberculous drugs
TB MENINGITIS and anti tuberculous drugs
 
Basic ventilatory parameters
Basic ventilatory parametersBasic ventilatory parameters
Basic ventilatory parameters
 
AHA BLS
AHA BLSAHA BLS
AHA BLS
 
Abg interpretation copy
Abg interpretation   copyAbg interpretation   copy
Abg interpretation copy
 
Trouble shooting of mechanical ventilator
Trouble shooting of mechanical ventilatorTrouble shooting of mechanical ventilator
Trouble shooting of mechanical ventilator
 
ACUTE MANAGEMENT OF Hyperkalemia
ACUTE MANAGEMENT OF Hyperkalemia ACUTE MANAGEMENT OF Hyperkalemia
ACUTE MANAGEMENT OF Hyperkalemia
 
diagnosis and management of mdr iai role of carbapenems and tigecycli.._
diagnosis and management of mdr iai role of carbapenems and  tigecycli.._diagnosis and management of mdr iai role of carbapenems and  tigecycli.._
diagnosis and management of mdr iai role of carbapenems and tigecycli.._
 
Role of vitamin c and thiamine in sepsis
Role of vitamin c and thiamine in sepsisRole of vitamin c and thiamine in sepsis
Role of vitamin c and thiamine in sepsis
 
NUTRITION IN CRITICAL CARE
NUTRITION IN CRITICAL CARENUTRITION IN CRITICAL CARE
NUTRITION IN CRITICAL CARE
 
Aspiration pneumonia
Aspiration pneumoniaAspiration pneumonia
Aspiration pneumonia
 
Ventilation in acute heart failure
Ventilation in acute heart failureVentilation in acute heart failure
Ventilation in acute heart failure
 
Ulinastatin final
Ulinastatin finalUlinastatin final
Ulinastatin final
 

Recently uploaded

NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
Dr. Ahana Haroon
 
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
ayushrajshrivastava7
 
Nano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory projectNano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory project
SIVAVINAYAKPK
 
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public HealthAgeing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
phuakl
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
suvadeepdas911
 
Giloy in Ayurveda - Classical Categorization and Synonyms
Giloy in Ayurveda - Classical Categorization and SynonymsGiloy in Ayurveda - Classical Categorization and Synonyms
Giloy in Ayurveda - Classical Categorization and Synonyms
Planet Ayurveda
 
PGx Analysis in VarSeq: A User’s Perspective
PGx Analysis in VarSeq: A User’s PerspectivePGx Analysis in VarSeq: A User’s Perspective
PGx Analysis in VarSeq: A User’s Perspective
Golden Helix
 
Local anesthetics 2024/ Medicinal Chemistry pdf
Local anesthetics 2024/ Medicinal Chemistry pdfLocal anesthetics 2024/ Medicinal Chemistry pdf
Local anesthetics 2024/ Medicinal Chemistry pdf
NarminHamaaminHussen
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
FFragrant
 
What are the different types of Dental implants.
What are the different types of Dental implants.What are the different types of Dental implants.
What are the different types of Dental implants.
Gokuldas Hospital
 
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
MuskanShingari
 
SENSORY NEEDS B.SC. NURSING SEMESTER II.
SENSORY NEEDS B.SC. NURSING SEMESTER II.SENSORY NEEDS B.SC. NURSING SEMESTER II.
SENSORY NEEDS B.SC. NURSING SEMESTER II.
KULDEEP VYAS
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
MedicoseAcademics
 
Recent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptxRecent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptx
DrGirishJHoogar
 
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
shruti jagirdar
 
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOWPune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Get New Sim
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Dr. Nikhilkumar Sakle
 
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International TravelersTravel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
NX Healthcare
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
LEFLOT Jean-Louis
 

Recently uploaded (20)

NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
 
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
 
Nano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory projectNano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory project
 
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public HealthAgeing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
 
Giloy in Ayurveda - Classical Categorization and Synonyms
Giloy in Ayurveda - Classical Categorization and SynonymsGiloy in Ayurveda - Classical Categorization and Synonyms
Giloy in Ayurveda - Classical Categorization and Synonyms
 
PGx Analysis in VarSeq: A User’s Perspective
PGx Analysis in VarSeq: A User’s PerspectivePGx Analysis in VarSeq: A User’s Perspective
PGx Analysis in VarSeq: A User’s Perspective
 
Local anesthetics 2024/ Medicinal Chemistry pdf
Local anesthetics 2024/ Medicinal Chemistry pdfLocal anesthetics 2024/ Medicinal Chemistry pdf
Local anesthetics 2024/ Medicinal Chemistry pdf
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
 
What are the different types of Dental implants.
What are the different types of Dental implants.What are the different types of Dental implants.
What are the different types of Dental implants.
 
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
 
SENSORY NEEDS B.SC. NURSING SEMESTER II.
SENSORY NEEDS B.SC. NURSING SEMESTER II.SENSORY NEEDS B.SC. NURSING SEMESTER II.
SENSORY NEEDS B.SC. NURSING SEMESTER II.
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
 
Recent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptxRecent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptx
 
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
 
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOWPune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
 
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International TravelersTravel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
 

Reversal of antithrombotic agent

  • 1. Reversal Of Antithrombotic Agents DR ANKIT GAJJAR MD,IDCCM,IFCCM,EDIC Consultant Intensivist at INS Hospital, Surat
  • 2. Antithrombotic Agents • Anti platelet drugs…. Aspirin, Clopidogrel • Anti coagulants Parenteral UFH LMWH…. Enoxaparin, Dalteparin Fondaparinux Oral Warfarin NOAC • Thrombolysis
  • 3. Vascular Injury Exposure of collagen and vWF Tissue factor exposure Platelet adhesion and release Activation of coagulation Platelet recruitment and activation Thrombin generation Fibrin formationPlatelet aggregation Platelet – fibrin thrombus
  • 4. • Drugs used in thrombosis • Anticoagulants: drugs which prevent clotting by inhibiting clotting factors (coagulation process) (used in prevention and treatment of thrombosis). • Antiplatelets: drugs which prevent and inhibit platelet activation and aggression (used as prophylactic therapy in high risk patients). • Thrombolytics or Fibrinolytics: act by dissolving existing or already formed thrombi or emboli and used in the acute treatment of thrombosis. •
  • 6. The role of platelets
  • 7. The role of platelets
  • 8. The role of platelets
  • 9. The role of platelets
  • 10. Plaque Disruption Collagen vWF Platelet adhesion and secretion Aspirin Ticlopidine Clopidogrel Abciximab Eptifibatide Tirofiban Platelet aggregation Platelet recruitment and activation COX-1 ADP GPllb / llla activation X Mechanisms of action of antiplatelet drugs X TXA2
  • 11.
  • 12.
  • 13. Antiplatelet Agents • Aspirin Irreversibly inhibit COX 1 enzyme Rapid onset <1 hr Half life 15- 30 minutes 5-7 days for platelet recovery
  • 14. Antiplatelet Agents • Clopidogrel • Irreversibly inhibit ADP receptor subtype P2Y12 receptor, required for platelet activation • Half life 8 hrs • 5 days for platelet recovery
  • 15. Antiplatelet Agents • Mixing of Aspirin treated platelets ex-vivo, with 30-50 % untreated donor platelets, restored abnormal platelets aggregation response. So, infusion of 2-3 adult dose of donor platelets are effective in emergency reversal of aspirin in adults. Vilahur et al 2007 Li et al 2012 British journal of Haematology 2012, 160, 35-46
  • 16. Antiplatelet Agents • Reversal Elective surgery wait for 5-7 days For emergency surgery, replacement with platelet transfusion should be consider For conservative management, platelet transfusion is not recommended (risk/benefit ratio) Desmopressin (0.4 micrg/kg) can be consider spcifically in patient with Uremia No role of FFP and Protamine Dastur CK, Stroke and Vascular Neurology 2017
  • 18.
  • 19.
  • 20.
  • 21.
  • 22. UFH • Acts on intrinsic pathway • Inactivates IX, X, XI and XII and thrombin and inhibit conversion of fibrinogen to fibrin • Metabolized in liver and reticulo endothelial system • No Renal adjustment • Dose : 60-80 Unit/kg bolus f/b 12-18 Unit/kg/hr Px - 5000 Unit Bd / Tid • Monitoring by aPTT level • Does not affect Prothrombin Time
  • 23. UFH • Shorter half life 30-90 minutes • Reversal If stopped before 4 hours, no need of any reversal If infusion is going on, calculate last 2-2.5 hours of heparin and give protamine sulphate 1 mg/100 unit of heparin (maximum 50 mg) If dose unknown, give 50 mg of protamine 100 % reversal effect Mesure aPTT before OT No role of FFP or Vitamin K
  • 24. LMWH • Enoxaparin and Dalteparin • Inhibit factor X>II • Does not affect aPTT and PT level • Renal clearance, so dose adjustment in renal failure • Dose: Therapeutic - I mg/kg bid or 1.5 mg/kg od (1 mg/kg od in renal failure) Prophylactic – 40 mg sc od • No need of monitoring (factor Anti Xa level can be monitored in special case)
  • 25. LMWH • Reversal For elective surgery, stop before 24 hours For immediate reversal, - last dose < 8 hours – 1 mg protamine / 1 mg enoxaparin (additional 0.5 mg protamine / 1 mg enoxaparin can be used) - last dose 8-12 hours – 0.5 mg protamine / 1 mg enoxaparin 60 % reversal No use of FFP or Vitamin K
  • 26. Fondaparinux • Indirect Factor Xa inhibitor • Does not affect aPTT and PT • No need of monitoring • Renal clearance (C/I if CrCl < 30 ml/min) • Dose : Prophylactic : 2.5 mg sc od Therapeutic : < 50 kg 5 mg sc od 50-100 kg 7.5 mg sc od > 100 kg 10 mg sc od
  • 27. Fondaparinux • Reversal Elective surgery stop before 24 hours No agent for immediate reversal Factor VIIa can be try
  • 28. Warfarin • Inhibit Vitamin K dependent factor II, VII, IX and X • Mesure PT for dose adjustment • Half life 36 hrs. • 5 days for INR to become normal • Target INR 2-3
  • 29. Warfarin • For immediate reversal of INR • Inj vit K 10 mg iv with PCC or FFP • PCC – 4 factor or 3 factor PCC 1500-2000 IU  Cost and availability  Rapid and specific reversal • FFP – 15 – 20 ml/kg (6-8 units of FFP)  Shorter duration of action  large volume infusion and more complication  Slow reversal than PCC Target INR <1.5
  • 30. Warfarin • Factor VIIa can be used • No role of protamine sulphate
  • 31. Warfarin • Supratherapeutic INR without bleeding • INR 5-9 – omit 1-2 dose+- 1.25 -5 mg PO vitamin K • INR >9 ( no bleed )- omit 1-2 dose +/- 2.5 - 5 mg PO vitamin K • Surgery Reversal INR > 1.5-2.5 hrs. • Sx <24 hrs – 0.5 -1 mg IV vit.K x1 +/- 5-8 ml/kg FFP • Sx 24-96 hrs- 0.5 -1 mg PO vitamin K INR > 2.5 – 5 • Sx <24 hrs – 1-2.5 IV Vitamin K +/- 5-8ml /kg FFP • Sx 24-96 hrs – 1-2.5 mg PO vitamin K
  • 32. Warfarin • For elective surgery • Stop warfarin before 5 days • Switch over to UFH / LMWH • Stop UFH / LMWH before surgery
  • 33. Dabigatran • NOAC • Direct thrombin inhibitor (Argatroban, bivalirudin) • Dose : 150 mg PO bd if CrCl 15-30 ml/min – 75 mg PO bd • No need of monitoring for therapeutic effect but Thrombin time will be elevated • No use of FFP or Protamine • Indication : Stroke prevention in non valvular AF
  • 34. Dabigatran • Reversal • For elective surgery, stop before 24 hours • For emergency reversal, Idarucizumab (Praxbind®) Infuse two 2.5 gram/50 mL vials undiluted over 5-10 minutes each - Second vial should be infused within 15 minutes of first vial • Activated Charcoal – within 1 hr. of Dabigatran • Dialysis – Last resort, removes 60% of dabigatran(mainly in renal failure) • 4 factor PCC (50 unit/kg) if Praxibind is not available • Factor VIIa can be tried • A normal aPTT and TT rules out clinically relavent Dabigatran effect.
  • 35. Factor Xa inhibitors • Rivaroxaban, Apixaban, Edoxaban • Elective surgery – stop before 24 hours • Emergency reversal • If presenting within 2 hours of intake – activated charcoal • 4 factor PCC – 50 units / kg • Laboratory testing not helpful • Not dialysable
  • 37. Thrombolytic agents • Cryoprecipitate 10 units • If fibrinogen <150 mg/dl post cryoprecipitate, consider additional cryoprecipitate • 6-8 unit of platelet concentrate • If cryoprecipitate not available, FFP can be given • If not available, than tranexamic acid 15-20 ml/kg
  • 38. Protamine Sulphate • Protamine is basic in nature and combine with acidic heparin • Calculate dose • Maximum dose 50 mg (1 ampoule) • Severe Allergic reaction • Administration Dilute in 5 ml of sterile water Inject over 10 minutes
  • 39. TAKE HOME MESSAGE DRUG Elective Emergency Not indicated Monitoring Aspirin Clopidogrel Stop before 5-7 days Platelet concentrate Desmopressin (Uremia) FFP Vitamin K Protamine None UFH Stop before 4-6 hours Protamine Sulphate (100%) FFP Vitamin K aPTT LMWH Stop before 24 hours Protamine Sulphate (60 %) FFP Vitamin K Anti Xa level Fondaperinux Stop before 24 hours FVIIa FFP Vitamin K Protamine Anti Xa level Warfarin Stop before 5-7 days Vitamin K 4 PCC 50 Unit/kg FFP 15-20 ml/kg Protamine PT
  • 40. Drug Elective Emergency Not indicated Monitoring Dabigatran Stop before 24 hours Activated Charcoal Praxbind 5 gm 4 factor PCC Dialysis FFP Vitamin K Protamine TT aPTT Rivaroxaban Stop before 24 hours Activated Charcoal 4 factor PCC FFP Vitamin K Protamine Dialysis None Thrombolytics --- 10 Cryoprecipitate 6-8 RDP FFP ---- Fibrinogen

Editor's Notes

  1. September 2007
  2. September 2007
  3. September 2007
  4. September 2007